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Introduction
As with problem drinking, gambling,
and narcotics use [1–9] population studies
show consistently that a large majority of
smokers who permanently stop smoking
do so without any form of assistance
[10–15]. In 2003, some 20 years after
the introduction of cessation pharmaco-
therapies, smokers trying to stop unaided
in the past year were twice as numerous as
those using pharmacotherapies and only
8.8% of US quit attempters used a
behavioural treatment [16]. Moreover,
despite the pharmaceutical industry’s ef-
forts to promote pharmacologically medi-
ated cessation and numerous clinical trials
demonstrating the efficacy of pharmaco-
therapy, the most common method used
by most people who have successfully
stopped smoking remains unassisted ces-
sation (cold turkey or reducing before
quitting [16,17]). In 1986, the American
Cancer Society reported that: ‘‘Over 90%
of the estimated 37 million people who
have stopped smoking in this country since
the Surgeon General’s first report linking
smoking to cancer have done so unaided.’’
[18]. Today, unassisted cessation contin-
ues to lead the next most successful
method (nicotine replacement therapy
[NRT]) by a wide margin [15,16].
Yet, paradoxically, the tobacco control
community treats this information as if it
was somehow irresponsible or subversive
and ignores the potential policy implica-
tions of studying self-quitters. Unassisted
cessation is seldom emphasised in advice
to smokers [19]. We know of no cam-
paigns that highlight the fact that most ex-
smokers quit unaided even though hun-
dreds of millions have done just that.
Reviews typically give unassisted cessation
cursory attention [20], framing it as a
challenge to be eroded by persuading
more smokers to use pharmacotherapies:
‘‘Unfortunately, most smokers …fail to use
evidence-based treatments to support their
quit attempts’’ [21]; ‘‘If there is a major
failing in the UK approach, it is not that it
has medicalised smoking, but that it has
not done so enough.’’ [22]. Clinical
guidelines also ignore unassisted cessation
[8]. Finally, although the US National
Center for Health Statistics routinely
included a question on ‘‘cold turkey’’
cessation in its surveys between 1983 and
2000, this question disappeared in 2005
[23].
Because of these prevalent attitudes,
smoking cessation is becoming increasing-
ly pathologised, a development that risks
distortion of public awareness of how most
smokers quit to the obvious benefit of
pharmaceutical companies. Furthermore,
the cessation research literature is preoc-
cupied with the difficulty of stopping.
Notably, however, in the rare literature
that has bothered to ask [24], many ex-
smokers recall stopping as less traumatic
than anticipated. For example, in a large
British study of ex-smokers in the 1980s,
before the advent of pharmacotherapy,
53% of the ex-smokers said that it was
‘‘not at all difficult’’ to stop, 27% said it
was ‘‘fairly difficult’’, and the remainder
found it very difficult [25].
We recently hypothesized that research
into smoking cessation follows what we
call ‘‘the inverse impact law of smok-
ing cessation.’’ This law posits that ‘‘the
volume of research and effort devoted to
professionally and pharmacologically me-
diated cessation is in inverse proportion
to that examining how most ex-smokers
actually quit. Research on cessation is
dominated by ever-finely tuned accounts
of how smokers can be encouraged to do
anything but go it alone when trying to
quit—exactly opposite of how a very large
majority of ex-smokers succeeded.’’ [26]
In this Policy Forum, we test this law
and, because a recent review of Cochrane
selected randomized controlled trials of
NRT [27,28] found that while 51% of
industry-funded trials reported significant
cessation effects, only 22% of nonindustry
trials did, we also test the hypotheses that
research on pharmaceutically mediated
cessation is frequently conducted by re-
searchers supported by pharmaceutical
companies and that support for research
into unassisted cessation and nonpharma-
ceutical interventions is less common.
Throughout this Policy Forum, by assisted
cessation, we mean any pharmacotherapy
or any individual or group behavioural or
cognitive intervention. By unassisted ces-
sation, we mean approaches that involve
none of these interventions but instead
include interventions such as changes
in tobacco tax, smoking restrictions, or
public awareness campaigns designed to
stimulate cessation. We then consider
why research into how most people stop
smoking is being neglected and reflect on
the potential negative consequences for
public health of repeatedly megaphoning
the message that ‘‘serious’’ cessation is
assisted cessation, a message that implies
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research attention, publicity, and consid-
eration by quitters. Finally, we suggest
how the message that smokers are getting
about cessation should be adjusted to help
more people quit.
Testing the Inverse Impact Law
of Smoking Cessation
On May 12, 2009, we searched Medline
for ‘‘smoking cessation,’’ limiting results to
English language original articles, meta-
analyses, and reviews published in 2007
and 2008. Of the 885 papers returned,
we excluded those that dealt specifically
with the effects of cessation on behaviour-
al, cognitive or affective variables, study
recruitment research, health economics,
and those papers that had a different
primary focus, such as smoking-related
diseases.
Of the 662 papers that met our
inclusion criteria, 511 were studies of
cessation interventions. The other 118
were mainly studies of the prevalence of
smoking cessation in whole or special
populations. Of the intervention papers,
467 (91.4%) reported the effects of assisted
cessation and 44 (8.6%) described the
impact of unassisted cessation (Figure 1).
Some of those quitting as a consequence of
unassisted cessation policies or programs
would have used assisted methods, but
these papers reported only on smoking
status, not on how those who quit did so.
Of the studies describing assisted interven-
tions, 247 (52.9%) involved pharmaco-
therapy and 220 (47.1%) nondrug inter-
ventions. Of the papers describing
cessation trends, correlates, and predictors
in populations, only 13 (11%) contained
any data on unassisted cessation.
We then randomly chose 30 papers that
considered assisted cessation interventions,
30 that considered unassisted cessation
interventions, and 30 that discussed the
prevalence of smoking cessation to test the
hypothesis these groups of papers would
not differ in terms of whether authors
and/or studies had received support from
a pharmaceutical company manufactur-
ing smoking cessation products. For pa-
pers that contained no declarations of
competing interests and/or pharmaceuti-
cal industry funding, we emailed the
corresponding authors to request this
information. Where no replies were re-
ceived, we examined these authors’ previ-
ous publications on cessation from the past
5 years for such declarations.
Of the 84 papers for which compet-
ing interest information was available, 12/
25 (48%) of pharmacotherapy interven-
tion studies, 3/29 (10.3%) of nonpharma-
cotherapy intervention studies, and 0/
30 of unassisted cessation studies had
at least one author declaring support
from a company manufacturing cessation
products and/or research funding from
such a company (p,0.001). Five of the
six authors who did not respond to
requests for information on competing
interests were previously involved in stud-
Summary Points
N Research shows that two-thirds to three-quarters of ex-smokers stop unaided.
In contrast, the increasing medicalisation of smoking cessation implies that
cessation need be pharmacologically or professionally mediated.
N Most published papers of smoking cessation interventions are studies or
reviews of assisted cessation; very few describe the cessation impact of policies
or campaigns in which cessation is not assisted at the individual level.
N Many assisted cessation studies, but few if any unassisted cessation studies, are
funded by pharmaceutical companies manufacturing cessation products.
N Health authorities should emphasise the positive message that the most
successful method used by most ex-smokers is unassisted cessation.
Figure 1. Focus of original research and reviews of 662 smoking cessation papers indexed by Medline, 2007–2008 (percent of all
papers). *, Pharmacotherapy: NRT only 57; bupropion only 19; varenicline only 26; combination/head-to-head trials 56; other pharmacotherapy 20;
pharmacotherapy versus nonpharmacotherapy 7; pharmacotherapy with counselling 49; meta-analyses/systematic reviews 8; reduced nicotine
cigarettes 2; smokeless tobacco 3. **, Nonpharmacotherapy: community cessation centres, groups, counselling 28; primary health care 29; hospital-
based or referrals 39; workplace programs 6; schools/youth 16; quitlines 26; phone or posted initiated by professionals 16; Web-based 32;
combination quitline/Web/calls 9; pamphlets/books 2; spirometry as motivator 2; acupuncture/acupressure 3; exercise 6; meta-analyses/systematic
reviews 6. ***, Trends, correlates and predictors. Whole or special populations 82; youth 16; primary health care 6; hospital patients 12; workplaces2 .
#, Three articles were unobtainable.
doi:10.1371/journal.pmed.1000216.g001
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cessation.
Why Does the Research
Concentrate on Assisted
Cessation?
With approximately two-thirds [16] to
three-quarters [15] of ex-smokers stopping
unaided, our finding that 91.3% of recent
intervention studies focused on assisted
cessation provides support for the inverse
impact law of smoking cessation [26],
although further studies are needed to
confirm that the bias towards studies on
assisted cessation interventions that we
discovered is a long-standing one and
not peculiar to the years we studied. We
believe there are three main synergistic
drivers of the research concentration on
assisted cessation and its corollary, the
neglect of research on the natural history
of unassisted smoking cessation. These
are: the dominance of interventionism in
health science research; the increasing
medicalisation and commodification of
cessation; and the persistent, erroneous
appeal of the ‘‘hardening’’ hypothesis.
The Dominance of Interventionism
Most tobacco control research is under-
taken by individuals trained in positivist
scientific traditions. Hierarchies of evi-
dence give experimental evidence more
importance than observational evidence
[29,30]; meta-analyses of randomized
controlled trials are given the most weight.
Cessation studies that focus on discrete
proximal variables such as specific cessa-
tion interventions provide ‘‘harder’’ causal
evidence than those that focus on distal,
complex, and interactive influences that
coalesce across a smoker’s lifetime to end
in cessation. Specific cessation interven-
tions are also more easily studied than the
dynamics and determinants of cessation in
populations [31]. Experimental research
focused on proximal relationships between
specific interventions and cessation poses
fewer confounding problems and sits more
easily within the professional norms of
scientific grant assessment environments,
which are populated largely by scientists
working within the positivist tradition.
The dominance of the experimental
research paradigm is amplified by phar-
maceutical industry support for drug trials.
More than half the papers we found on
assisted cessation were pharmaceutical
studies and, unsurprisingly, these were
much more likely than papers on non-
pharmacological interventions to have
industry-supported authors. Companies
have an obvious interest in research about
the use and efficacy of their products
and less interest in supporting research
into forms of cessation that compete
with pharmacotherapy for the cessation
market.
The availability of pharmaceutical in-
dustry research funding—often provided
without the lengthy processes of open
tender or independent peer review—can
be highly attractive to researchers. Fur-
thermore, it is often observed that ‘‘re-
search follows the money,’’ with scientists
being drawn to well-funded research areas
[32]. The large pool of research funding
for pharmacotherapeutic cessation may
cause researchers to gravitate toward such
studies while those interested in the
natural history of smoking cessation have
to secure funding through highly compet-
itive public grant schemes.
This greater availability of funding for
certain sorts of research produces a
distorted research emphasis on pharmaco-
therapy that, when combined with the
industry’s formidable public relations
abilities and direct-to-consumer advertis-
ing, concentrates both scientific and public
discourse on cessation around assisted
pharmacotherapy. In 2006, the global
NRT market was estimated at $1.7 billion
[33]. The pharmaceutical industry places
more messages about quitting in front of
smokers than any other source: in the
USA, there are 10.37 pharmaceutical
cessation advertisements per month but
only 3.25 government and NGO cessation
messages [34].
The Medicalisation and
Commodification of Cessation
Tobacco use, like other substance use,
has become increasingly pathologised as a
treatable condition as knowledge about
the neurobiology, genetics, and pharma-
cology of addiction develops. Meanwhile,
the massive decline in smoking that
occurred before the advent of cessation
treatment is often forgotten. Warner [35]
documented this decline, which started
following news coverage of the 1964
report of the US Surgeon General. He
noted that ‘‘per capita consumption likely
would have exceeded its actual 1975 value
by 20 to 30 per cent’’ without this decline.
Other than the first small pack warnings
that appeared from 1966 in the USA, this
effect occurred without any elements of
today’s comprehensive approaches to to-
bacco control.
In 1975, Renaud wrote of the funda-
mental tendency of capitalism to ‘‘trans-
form health needs into commodities …
When the state intervenes to cope with
some health-related problems, it is bound
to act so as to further commodify health
needs.’’ [36]. The burgeoning commodifi-
cation of cessation by manufacturers of
both effective and ineffective [37] drugs
seems to have induced a kind of profes-
sional amnesia in tobacco control circles
about the millions who quit in the decades
before the dominance of the contempo-
rary smoking cessation discourse by phar-
macotherapy. As Granfield and Cloud
remarked about the substance abuse field’s
aversion to studying unassisted recovery
by narcotics addicts, the dominance of
assisted cessation in the tobacco control
field ‘‘has a common tendency to exclude
the experiences of people who do not fit
into prevailing models of substance prob-
lems and treatment’’ [2].
The Persistent, Seductive, and
Erroneous Appeal of the
‘‘Hardening’’ Hypothesis
This hypothesis predicts that where
‘‘smoking prevalence is lowest or the most
progress in reducing smoking prevalence
has been made, the remaining smokers are
more likely to be ‘hard-core’, or refractory
to a policy and/or treatment interventions,
because the people who have quit were
less dependent on nicotine, and/or more
motivated to quit.’’ [38]. The intuitive
attractions of this hypothesis generated an
entire US National Cancer Institute
monograph [39]. Hardening adherents
argue that ex-smokers are dominated by
those who were not heavily addicted and
so who were better able to quit unaided
and that a greater proportion of today’s
smokers, said to be more addicted, cannot
succeed alone and need help. This hy-
pothesis has been heavily criticised [40].
Most recently, data on smoking in 50 US
states for 2006–2007 indicate that the
mean number of cigarettes smoked daily,
the percentage of cigarette smokers who
smoke within 30 minutes of waking, and
the percentage who smoke daily are all
significantly lower in US states with low
smoking prevalence, compelling evidence
against the hardening hypothesis [38].
Does Research into Assisted
Cessation Apply to the Real
World?
Accumulated evidence from clinical
trials shows unequivocally that those who
use NRT in trials have 50%–70% greater
success than those using placebo [28]. But
clinical trial conditions typically overstate
real world effectiveness because of factors
such as trial participants getting free drugs
and ‘‘Hawthorne’’ effects caused by the
research attention paid to participants [41]
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researchers with whom they interact.
Moreover, Mooney et al. [42] found that
only 23% of NRT placebo-controlled
trials assessed blindness integrity and
71% of these trials found that the
participants could detect if they had been
assigned to the active agent, a rate
significantly above chance.
The results from a smaller, but growing,
literature examining ‘‘real world’’ use
provides a more sobering assessment of
the potential of this intervention to signifi-
cantly improve population rates of cessa-
tion. Walsh’s review concluded that it is
‘‘not yet established that NRT alone is
superior to self-quitting in an unsupported
OTC [over the counter] environment’’ [41]
and noted major limitations in Hughes’
earlier, more optimistic meta-analysis [43].
For the clinical trial efficacy of NRT to
be replicated in the real world, smokers
may need to have some form of support
during their cessation efforts but few
smokers are interested in engaging with
smoking cessation support services. In
Australia, for example, in spite of the
national quitline number appearing on
every cigarette pack and in every govern-
ment quit message, only 3.6% of smokers
called the quitline in a year [44]. In 2000–
2004, in the UK area with the highest
reported cessation support participation
rate, only 6% of smokers used the
available support services [45]. Prospects
for engaging larger proportions of smokers
in more intensive interventions seem poor.
Overall, population level analyses of the
impact of the proliferation, deregulation,
and widespread promotion of NRT and
other pharmacotherapies have failed to
show any significant, sustained impact on
smoking prevalence, despite the conclu-
sions of clinical trials. Cummings and
Hyland’s 2005 review concluded that:
‘‘Time series analyses of national cigarette
consumption and NRT sales from 1976 to
1998 suggest that sales of NRT were
associated with a modest decrease in
cigarette consumption immediately follow-
ing the introduction of the prescription
nicotine patch in 1992. However, no
statistically significant effect was observed
after 1996, when the patch and gum
became available OTC. … annual quit
rates as well as age-specific quit ratios
remained stable’’ [46]. Similar conclusions
were reached for Massachusetts [47] and
California [48]. Most recently, Wakefield
et al. assessed the impact of televised
antismoking advertising, cigarette price,
sales of NRT and bupropion (a smoking
cessation drug), and NRT advertising by
examining monthly Australian smoking
prevalence from 1995 to 2006. They
found that, unlike antismoking advertising
and price, neither NRT or bupropion sales
nor NRT advertising had any detectable
impact on smoking prevalence [49]. Al-
though this lack of effect may have been
due to power limitations (some 40% of
smokers make an attempt to quit each
year, a fraction of these use pharmaceuti-
cal aids, and an even smaller fraction quit,
which means that extremely large popula-
tion samples are needed to detect any
effect of these interventions), it hardly
inspires confidence that assisted cessation
makes a major contribution to reducing
smoking in populations.
The public is often advised that assis-
tance at least doubles cessation rates. But
while the clinical trial literature consistent-
ly shows higher quit rates from assisted
than unassisted cessation, population stud-
ies show the opposite. For example, a 1990
US study found 47.5% of those who tried
to quit unaided over 10 years were
successful, compared with 23.6% using
cessation programs [10]. Schachter noted
that treatment-aided cessation rates may
be lower than unassisted quit rates because
of selection bias: those seeking treatment
are likely to have made unsuccessful quit
attempts and may be more failure-prone
[50]. In 2008, Shiffman et al. reiterated
this point: ‘‘Further, smokers self-select for
treatment, based on their perceived need
and expectations of difficulty quitting …so
treatment-seeking itself can index risk for
failure, undermining the validity of com-
parisons of outcome between treatment-
seekers and non-seekers.’’ [16,51].
A final example of how promoters of
assisted cessation can maintain their posi-
tion in the face of apparently contradictory
results comes from a recent US study of
unplanned cessation [52], which corrobo-
rated previous findings [53,54] by report-
ing that unplanned cessation attempts
were twice as successful as planned
attempts and, significantly, that most
unplanned quit attempters did not use
any assistance. The authors noted that:
‘‘Given the evidence that use of medica-
tion can double success rates, it is
surprising that even without this assistance
unplanned quitters were more likely to be
successful. It seems important to find ways
to combine the favorable prognosis of
unplanned quit attempts with the benefit
of medication, for example, by ensuring
easy, rapid access to medication.’’ They
then suggested the removal of barriers to
NRT sale such as prescription-only or
pharmacy-only status, failing to note that
these barriers had already been removed
in the USA. The ‘‘surprise’’ expressed by
the authors of this paper (all of whom had
declared support from the pharmaceutical
industry) seems revelatory of the myopic
hold that assisted smoking cessation can
have on the population-wide picture of
how people quit.
The Consequences of the
Research Neglect of Unassisted
Cessation
There has been a long history of
criticism of the medicalisation of everyday
life [55] to service social control [56] and
medical and pharmaceutical industry prof-
its [57]. As Caron et al. note: ‘‘the classic
drawback of medicalization is its reduc-
tionism, which places excessive emphasis
on the biological and individual determi-
nants of disease at the expense of a more
holistic perspective that emphasizes the
social, cultural, and environmental contri-
butions to disease and illness.’’ [58]. The
neurobiology of nicotine dependency is
well-established [59], and understanding
of its genetics [60] is accelerating. But
plainly, with the existence of many
millions of unassisted ex-smokers and
given the ways that international varia-
tions in their distribution reflect social,
cultural, and public-health policy vari-
ables, smoking cessation in populations is
explained by far more than neurobiology
and pharmacology.
The persistent messaging that nicotine
addiction is refractory and stopping unaid-
edwillbefutiledeflectsattentionawayfrom
what is by far the most common story of
cessation: people doing it without profes-
sional or therapeutic help. When citizens
have common, self-limiting ailments and
traits and behaviours are regularly rede-
fined as needing treatment, avoidable
iatrogenic consequences and burgeoning
health care expenditure can follow. But the
steady erosion of human agency as popu-
lations lose confidence in their own ability
to change unhealthy practices is perhaps of
greater concern. Several negative conse-
quences arise from smokers being increas-
ingly imbued with the message that serious
efforts at cessation require treatment.
It is understandable that smokers might
feel it would be foolish to attempt to stop
unaided when unassisted cessation is
dismissed in pharmaceutical industry–sup-
ported demonstrably misleading propa-
ganda [61] by statements such as: ‘‘It is
hopelessly outdated to suggest: ‘willpower
alone is enough to quit’. … Quitting ‘cold
turkey’ does not generally translate into
sustained abstinence from tobacco, and
results in unnecessarily low rates of success
for most smokers.’’ [62]; and: ‘‘[the]
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addiction …[has] conceivably perpetuated
the epidemic [and] contributed to innu-
merable deaths’’ [62]. Because most
assisted cessation attempts end in relapse,
such ‘‘failure’’ risks are interpreted by
smokers as ‘‘I tried and failed using a
method that my doctor said had the best
success rate. Trying to quit unaided –
which I never hear recommended – would
be therefore sheer folly.’’ Such reason-
ing might well disempower smokers and
inhibit quit attempts through anticipatory,
self-defeating fatalism [63].
Why Study Unassisted
Cessation?
In any endeavour, whether it be health-
related such as weight loss, physical
activity or ending narcotics use, or wider
achievements such as business success or
artistic virtuosity, it would seem reason-
able to consider that studying those who
had succeeded or excelled might reveal
factors that might be valuable to others.
Studying the habits, attitudes, routines,
and environments of people who succeed
where many others fail is commonplace in
other fields so why not study unassisted
smoking cessation?
The relatively few studies reporting on
people who have quit unaided provide
important information about factors asso-
ciated with motivating quit attempts and
with successful unaided cessation. Some of
these factors are amenable to change via
legislation or mass-reach public-awareness
campaigns. Smoke-free homes [15] and
workplaces [64], family and social support
[65], bold pack warnings [66], price, and
hard-hitting, well-funded campaigns [49]
have all been associated with increased
cessation activity and success, and relapse
has been associated with exposure to social
smoking cues [67].
Warner and Mackay argue that: ‘‘We
can have our cake and eat it too’’ [68],
stating that further resources and empha-
sis should be given to treating tobacco
dependence as well as to public-health,
population-focused approaches to promot-
ing cessation. Certainly, smoking cessation
treatment is one of the most cost-effective
interventions in modern medicine [69],
and wealthy nations can afford both
approaches. However, today’s largest to-
bacco markets are nations with massive
populations on low incomes for whom
pharmacotherapy is prohibitively expen-
sive. In Indonesia for example, 3 months
of NRT costs as much as 7 year’s supply of
cigarettes, placing NRT totally out of the
reach of all but the wealthy [70]. NRT
would thus seem to be largely irrelevant to
population-wide cessation goals in many
low- and middle-income nations.
Such nations emphatically cannot af-
ford ‘‘both’’ and are often still struggl-
ing to fund basic primary health care,
public-health, and sanitation infrastruc-
tures. Population-oriented, mass-reach to-
bacco control policy and programs are the
exceptions in such nations. In our view, it
would be a disaster for tobacco control
progress if such nations were to be
influenced to proliferate labour-intensive
UK-style [71] models of assisted cessation
before they implemented comprehensive
and sustained population-focused cessa-
tion policies and programs. In most
nations, tobacco control is in its nascent
phase. Siphoning resources and scarce
personnel into smoking cessation strategies
that reach relatively few and help even
fewer would be grossly inequitable.
What Message Should Smokers
Get about Cessation?
The persistence of unassisted cessation
as the most common way that most
smokers have succeeded in quitting is an
unequivocally positive message that, far
from being suppressed or ignored, should
be openly embraced by primary health
care workers and public-health authorities
as the front-line, primary ‘‘how’’ message
in all clinical encounters and public
communication about cessation. Put an-
other way, a failure to emphasise that
most smokers have always stopped unaid-
ed would be like claiming that most
domestic cooks attend cooking classes.
Along with motivational ‘‘why’’ messages
designed to stimulate cessation attempts,
smokers should be repeatedly told that
cold turkey and reducing-then-quitting
are the methods most commonly used by
successful ex-smokers, that more smokers
find it unexpectedly easy or moderately
difficult than find it very difficult to quit
[25], that many successful ex-smokers
do not plan their quitting in advance
[52–54], and that ‘‘failures’’ are a normal
part of the natural history of cessation—
rehearsals for eventual success. Lessons
learned from researching policy tractable,
social support, and personal behavioural
(‘‘quit tips’’) variables associated with
successful cessation should be fed into
policy and program planning. Talk of
unassisted cessation being ‘‘the enemy’’
of evidence-based cessation should be
roundly criticised as both incorrect and
unhelpful. Unfortunately, the ability of
manufacturers to promote their products
through advertising is likely to ‘‘drown
out’’ the perspective we urge. We suggest,
therefore, that public sector communica-
tors should be encouraged to redress the
overwhelming dominance of assisted ces-
sation in public awareness, so that some
balance can be restored in smokers’ minds
regarding the contribution that assisted
and unassisted smoking cessation ap-
proaches can make to helping them quit
smoking.
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